170 unknown, 168 recruiting, 142 completed, 83 not yet recruiting. 678 Phase 2, 76 Phase 1, 55 Phase 3.
Follow Drug Therapy: new trials by email Literature Review of Drug Therapy trials Research Report on Drug Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine | Phase 2 | Not yet recruiting | Xiang-Qian | 120 | 2027-09-01 | 2026-08-27 |
| Cannabis Gummy for the Improvement of Sleep and Quality of Life in Patients With Cancer, Pillow Trial Actigraphy, Best Practice, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Theodore Brasky PhD | 50 | 2027-01-15 | 2026-10-14 |
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy, Cemiplimab, Chemotherapy - Glioblastoma, Glioblastoma, IDH-wildtype | Phase 2 | Not yet recruiting | Washington University School of Medicine | 99 | 2026-11-30 | 2026-10-20 |
| Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma Ivonescimab Combined With Chemotherapy - Malignant Pleural Mesothelioma, Advanced | Phase 1 / Phase 2 | Recruiting | Ruijin Hospital | 78 | 2026-11-01 | 2026-10-26 |
| SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer SSGJ-706, SPGL008, Chemotherapy - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | 220 | 2026-11-01 | 2026-10-15 |
| Fecal Microbiota Transplantation Combined With NALIRIFOX Plus Serplulimab as First-line Treatment for Advanced or Metastatic Pancreatic Ductal Adenocarcinoma. FMT combined with chemotherapy plus immunotherapy, Chemotherapy+Immunotherapy - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 40 | 2026-11-01 | 2026-10-02 |
| Off-Label Treatment With Immune Checkpoint Inhibitor Blockade One or more off-label ICIs alone or with other on-label ICI(s), Off-label ICI(s) with targeted therapy, off-label ICI(s) with other agents that are not targeted (including, but not limited to, chemotherapy, hormonal therapy, immunotherapy other than ICIs) with or without targeted agents - Malignancy | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 231 | 2026-11-01 | 2026-08-10 |
| Optimizing Response to Immunotherapy With Online Adaptive Pulsed Radiotherapy in Incurable Head and Neck Cancers Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy - Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Not yet recruiting | University Health Network, Toronto | 48 | 2026-11-01 | 2026-10-22 |
| Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases Immunotherapy, Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin), low-dose radiation - Lung Cancer (SCLC) | Phase 2 | Not yet recruiting | Sichuan University | 30 | 2026-10-31 | 2026-05-05 |
| A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment Chemotherapy, Immunotherapy, Intensity-Modulated Radiation Therapy - Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 164 | 2026-10-14 | 2026-10-19 |
| Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms Topotecan - usual, Topotecan - study - SCLC | Phase 2 / Phase 3 | Active not recruiting | Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | 600 | 2026-10-05 | 2026-10-08 |
| THC Versus THC/CBD Versus Placebo to Improve Sleep Quality for Patients With Solid Organ Cancer and Insomnia Biospecimen Collection, Placebo Administration, Single Agent Therapy - Insomnia, Malignant Solid Neoplasm | Phase 2 | Not yet recruiting | Mayo Clinic | 69 | 2026-10-01 | 2026-09-02 |
| Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors PD-1 and chemotherapy, cryoablation - Biliary Tract Cancer (BTC) | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2026-10-01 | 2026-07-24 |
| 16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer 16-Hour Fasting, Serplulimab + chemotherapy - pMMR/MSS, Locally Advanced Rectal Carcinoma | Phase 2 | Not yet recruiting | Zhejiang University | 51 | 2026-10-01 | 2026-09-08 |
| Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC Pembrolizumab, Paclitaxel (Chemotherapy), Carboplatin - Triple-Negative Breast Cancer (TNBC) | Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 60 | 2026-10-01 | 2026-08-26 |
| Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited Metastases Retlirafusp alfa Combined with Targeted Therapy and Chemotherapy - Colorectal Adenocarcinoma Metastatic in the Liver | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 80 | 2026-09-30 | 2026-09-11 |
| Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer NaCET: For chemotherapy, the TEC or EC-T regimen is selected; for endocrine therapy, letrozole is administered; for premenopausal patients, an LHRH agonist-goserelin or leuprolide - Invasive Breast Cancer (Stage I-III) | Phase 2 | Not yet recruiting | The Second Hospital of Anhui Medical University | 36 | 2026-09-30 | 2026-09-03 |
| Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer Adebrelimab, Thymalfasin, Chemotherapy - Esophageal Cancer | Phase 2 | Not yet recruiting | The Affiliated Hospital of Putian University | 31 | 2026-08-30 | 2026-08-21 |
| Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma Pemigatinb, PD-1 inhibitors, Chemotherapy - Biliary Tract Cancer (BTC) | Phase 2 | Recruiting | Haitao Zhao, MD | 154 | 2026-08-20 | 2026-08-26 |
Showing 20 of 678. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (95) · Breast Neoplasms (45) · Colorectal Neoplasms (35) · Neoplasms (31) · Lung Neoplasms (28) · Rectal Neoplasms (27) · Esophageal Squamous Cell Carcinoma (26) · Esophageal Neoplasms (25) · Stomach Neoplasms (25) · Pancreatic Neoplasms (24) · Neoplasm Metastasis (22) · Head and Neck Neoplasms (20) · Squamous Cell Carcinoma of Head and Neck (19) · Ovarian Neoplasms (17) · Small Cell Lung Carcinoma (15)
Fudan University (28) · Sun Yat-sen University (20) · Tianjin Medical University Cancer Institute and Hospital (16) · Peking Union Medical College Hospital (9) · Pfizer (9) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (8) · M.D. Anderson Cancer Center (8) · Sichuan University (8) · Shanghai Chest Hospital (7) · Shanghai Pulmonary Hospital, Shanghai, China (7) · Zhejiang University (7) · National Cancer Institute (NCI) (6) · Zhejiang Cancer Hospital (6) · Harbin Medical University (5) · Ruijin Hospital (5)
China (289) · United States (163) · France (42) · Italy (32) · Germany (31) · Spain (27) · Canada (19) · South Korea (17) · Netherlands (16) · Belgium (14) · United Kingdom (13) · Poland (11) · Egypt (10) · Israel (10) · Russia (9)
Hongmeng Yu, MD,PHD (3) · You Lu, MD (3) · Adam Ostrowski, MD (2) · Dominique Elias, MD (2) · Haiyan Liu (2) · Huajun Jin (2) · Hui Liu, Professor (2) · Jiangtao Wang (2) · Jianguo Sun, MD (2) · Keith Cengel, MD, PhD (2) · Lei Li, M.D. (2)
PMID 40812353, PMID 28596308, PMID 30062662, PMID 37280366, PMID 38572751, PMID 10473315, PMID 10581077, PMID 10655437, PMID 11171826, PMID 11556297, PMID 11675328, PMID 11937316, PMID 12177103, PMID 12434281, PMID 14506149, PMID 14645425, PMID 15812833, PMID 15928658, PMID 16011702, PMID 16078267, PMID 16135463, PMID 16155013, PMID 16265674, PMID 16510333, PMID 16598416, PMID 16645718, PMID 17366834, PMID 17544337, PMID 17647306, PMID 17909941, PMID 18217208, PMID 18358930, PMID 18577561, PMID 18981007, PMID 18990510, PMID 19147777, PMID 19491285, PMID 19515503, PMID 19957326, PMID 19985059, PMID 20060381, PMID 20065174, PMID 20375404, PMID 20694800, PMID 20708924, PMID 20842054, PMID 20921456, PMID 20974795, PMID 21073974, PMID 21087935
2016 (5), 2025 (5), 2017 (3), 2023 (3), U10CA180820 (3), 2015 (2), 2018 (2), P30CA012197 (2), P30CA033572 (2), U24CA076518 (2), 2009 (1), 2014 (1), 2019 (1), P30CA006973 (1), P30CA016672 (1)